Neola Medical

08/06/2026

CEO Hanna Sjöström will deliver a live, on-site presentation at Aktiedagarna in Stockholm on June 10, 2026, at 08:50 CET at Birger Jarl Konferens.
“Neola Medical is entering an important next phase, building on positive safety results from our first clinical pilot study and a sharpened focus on lung collapse detection. At Aktiedagarna, I look forward to presenting our continued preparations toward the U.S. market and how the ongoing rights issue supports this next step,” says Hanna Sjöström, CEO of Neola Medical.

If unable to attend in Stockholm, the presentation will be streamed online at the following link: https://lnkd.in/dSrRd3Sc

The presentation will also be accessible for viewing afterward at www.neolamedical.com

19/05/2026

📣 Neola Medical today released the Q1 report of 2026! 📘👶🏻
“The first quarter of 2026 marked an important milestone for Neola Medical with the completion of enrollment and final results from our first clinical study on preterm born babies. The study represented the first real-world use of Neola® in its intended patient population within neonatal intensive care and confirmed a favorable safety profile across the studied patient population, including very low birth weight preterm born babies.”, says CEO Hanna Sjöström

05/05/2026

Neola Medical today publishes its Annual Report for 2025.

”2025 is the year when Neola is used for the first time for monitoring of the lungs of preterm born babies in intensive care,” says CEO Hanna Sjöström.

Read the full report here:https://storage.mfn.se/56fc16b2-6ee6-47da-9f0d-d02beb396aec/arsredovisning-neola-medical-2025.pdf

28/04/2026

Neola Medical announces rights issue, supported by main shareholders, to fund the next phase until regulatory approval in the U.S.

21/04/2026

🌟 New Redeye Interview with CEO Hanna Sjöström

In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the reported positive safety results from Neola Medical’s first clinical pilot study, key insights and the next phase of clinical development.

🎥 Watch the full interview here:

In a new interview with Redeye analyst Gustaf Meyer, CEO Hanna Sjöström discusses the reported positive safety results from Neola Medical’s first clinical pilot study, key insights and the next phase of clinical development. Watch the full interview here: Redeye Interview Neola Medical Reports P...

21/04/2026

📣 Neola Medical Reports Positive Safety Results from First Clinical Pilot Study and Advances Towards Next Phase of Clinical Development

“We are encouraged by the results confirming the favourable safety profile of Neola®,” says CEO Hanna Sjöström. “Importantly, the study has provided valuable insights into how the technology performs in a clinical setting, helping to define the optimization of the device. We now have a clear understanding of where Neola® can deliver the greatest clinical value, particularly in the detection of life-threatening lung complications in preterm born babies. We are sharpening our product offering by introducing lung collapse detection as a key capability, providing continuous monitoring with decision support for timely intervention.”

💡 Read more in the press release here: https://neolamedical.com/mfn_news/neola-medical-reports-positive-safety-results-from-first-clinical-pilot-study-and-advances-towards-next-phase-of-clinical-development/

16/03/2026

📣 Neola Medical Completes Enrollment in Swedish Clinical Pilot Study 👶🫁

All ten babies have now been included in the study, marking an important milestone with the first real-world use of Neola® in its target patient population in neonatal intensive care. 🌟

💡 Read more in the press release here: https://neolamedical.com/mfn_news/neola-medical-completes-enrollment-in-swedish-clinical-pilot-study/

12/02/2026

Did you miss Neola Medical’s Q4 report presentation hosted by Investor Studios?

Catch up on the highlights from Neola Medical’s year-end Q4 report for 2025. CEO Hanna Sjöström reflects on a year marked by key milestones as we entered the clinical phase, strengthened the organization, and continued to build on our most strategically important assets. CFO David Folkesson presents the financial results for Q4 2025.

🎥 Watch the report presentation and stay for the Q&A session here:

On the 12th of February at 11.00 CET, CEO Hanna Sjöström and CFO David Folkesson from Neola Medical will present the company’s earnings for the fourth quarte...

12/02/2026

📣 Neola Medical today released the Q4 report of 2025! 📘👶🏻 – Advancing IP Protection as a Core Strategic Asset across Key Markets

“This year we initiated our first clinical pilot study on preterm born babies in Sweden, representing the first real-world use of Neola® for continuous monitoring of its target patient population.”, says CEO Hanna Sjöström

💡 Read the entire press release and the report at our website: https://neolamedical.com/mfn_news/neola-medical-q4-report-2025-advancing-ip-protection-as-a-core-strategic-asset-across-key-markets/

🎥 Don’t miss when CEO Hanna Sjöström and CFO David Folkesson presents the Q4 report today at 11 am (CET). Watch the presentation here: https://youtube.com/live/-_0FXFp8uXM

06/02/2026

📢 Medtech Leaders and Clinical Expert Call for MDR Reform in Dagens industri

In a debate article published in Dagens Industri, four medtech CEOs, including Neola Medical’s CEO Hanna Sjöström, together with a professor at Lund University and senior clinician at Skåne University Hospital, highlight how the EU MDR framework is slowing innovation and driving investment away from Europe. 🇪🇺

As MDR is currently under review, the authors outline concrete steps to restore a more innovation-enabling regulatory pathway while maintaining high standards of patient safety.

💡 The debate article in Dagens industri is available to read (in Swedish) here: https://www.di.se/debatt/regelbordan-kvaver-svensk-medtech/